EOC
MCID: OVR094
MIFTS: 39

Ovarian Epithelial Cancer (EOC)

Categories: Cancer diseases, Rare diseases

Aliases & Classifications for Ovarian Epithelial Cancer

MalaCards integrated aliases for Ovarian Epithelial Cancer:

Name: Ovarian Epithelial Cancer 53 29 6
Epithelial Ovarian Cancer 53 72
Ovarian Epithelial Carcinoma 53
Ovarian Cancer, Epithelial 53
Eoc 53

Classifications:



External Ids:

UMLS 72 C0677886

Summaries for Ovarian Epithelial Cancer

MalaCards based summary : Ovarian Epithelial Cancer, also known as epithelial ovarian cancer, is related to cervical cancer and osteogenic sarcoma. An important gene associated with Ovarian Epithelial Cancer is PIK3CA (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha). The drugs Dexamethasone and Dexamethasone acetate have been mentioned in the context of this disorder. Affiliated tissues include ovary, breast and t cells.

Related Diseases for Ovarian Epithelial Cancer

Diseases related to Ovarian Epithelial Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 304)
# Related Disease Score Top Affiliating Genes
1 cervical cancer 29.9 PIK3CA CCAT2 CCAT1
2 osteogenic sarcoma 29.8 CCAT2 CCAT1
3 glioma 29.6 PIK3CA CCAT2 CCAT1
4 gastric cancer 28.7 PIK3CA DLEU1 CCAT2 CCAT1
5 breast cancer 28.3 PIK3CA DLEU1 CERNA2 CCAT2 CCAT1
6 ovarian cancer 28.1 PIK3CA ERLNC1 DNM3OS CERNA2 CCAT2 CCAT1
7 malignant epithelial tumor of ovary 11.8
8 ovarian clear cell carcinoma 11.6
9 primary peritoneal carcinoma 11.3
10 ovary transitional cell carcinoma 11.3
11 alopecia 10.5
12 neuropathy 10.5
13 peripheral nervous system disease 10.5
14 fallopian tube carcinoma 10.5
15 thrombocytopenia 10.5
16 thrombocytosis 10.5
17 clear cell adenocarcinoma 10.4
18 ovarian disease 10.4
19 mucinous adenocarcinoma 10.4
20 mucinous cystadenocarcinoma 10.4
21 appendix adenocarcinoma 10.4
22 infertility 10.4
23 ileus 10.4
24 severe combined immunodeficiency 10.3
25 insulin-like growth factor i 10.3
26 body mass index quantitative trait locus 1 10.3
27 47,xyy 10.3
28 sensory peripheral neuropathy 10.3
29 stomatitis 10.3
30 granulocytopenia 10.3
31 familial ovarian cancer 10.3
32 malignant glioma 10.3 CCAT1 ADAMTS9-AS1
33 colorectal cancer 10.3
34 ovarian serous carcinoma 10.3
35 endometriosis of ovary 10.3
36 constipation 10.3
37 lynch syndrome 10.3
38 b-cell lymphoma 10.3
39 acute sensory ataxic neuropathy 10.3
40 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.2
41 epileptic encephalopathy, childhood-onset 10.2
42 pelvic inflammatory disease 10.2
43 diarrhea 10.2
44 ovarian cystadenoma 10.2
45 adenoma 10.2
46 cytokine deficiency 10.2
47 retinoblastoma 10.2
48 body mass index quantitative trait locus 11 10.2
49 deficiency anemia 10.2
50 exanthem 10.2

Graphical network of the top 20 diseases related to Ovarian Epithelial Cancer:



Diseases related to Ovarian Epithelial Cancer

Symptoms & Phenotypes for Ovarian Epithelial Cancer

Drugs & Therapeutics for Ovarian Epithelial Cancer

Drugs for Ovarian Epithelial Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 438)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
2
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
3
Olaparib Approved Phase 4 763113-22-0 23725625
4 HIV Protease Inhibitors Phase 4
5
protease inhibitors Phase 4
6 BB 1101 Phase 4
7 Autonomic Agents Phase 4
8 Poly(ADP-ribose) Polymerase Inhibitors Phase 4
9
Melphalan Approved Phase 3 148-82-3 460612 4053
10
Sodium citrate Approved, Investigational Phase 3 68-04-2
11
Trabectedin Approved, Investigational Phase 3 114899-77-3 108150
12
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
13
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
14
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
15
Ondansetron Approved Phase 3 99614-02-5 4595
16
Pertuzumab Approved Phase 3 145040-37-5, 380610-27-5 2540
17
Ribavirin Approved Phase 3 36791-04-5 37542
18
Palivizumab Approved, Investigational Phase 3 188039-54-5
19
Captopril Approved Phase 3 62571-86-2 44093
20
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
21
Caspofungin Approved Phase 3 179463-17-3, 162808-62-0 468682 2826718
22
Acyclovir Approved Phase 3 59277-89-3 2022
23
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
24
Rucaparib Approved, Investigational Phase 3 283173-50-2 9931954
25
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
26
Gemcitabine Approved Phase 3 95058-81-4 60750
27
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 5310940 9887054 43805 6857599
28
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
29
Talazoparib Approved, Investigational Phase 3 1207456-01-6 135565082
30
Adenosine Approved, Investigational Phase 3 58-61-7 60961
31
Ropivacaine Approved Phase 3 84057-95-4 71273 175805
32
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
33
Doxorubicin Approved, Investigational Phase 2, Phase 3 23214-92-8 31703
34
Atezolizumab Approved, Investigational Phase 2, Phase 3 1380723-44-3
35
Topotecan Approved, Investigational Phase 3 123948-87-8, 119413-54-6 60700
36
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
37
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
38
Norgestimate Approved, Investigational Phase 3 35189-28-7 6540478
39
Moxifloxacin Approved, Investigational Phase 3 354812-41-2, 151096-09-2 152946
40
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
41
Polyestradiol phosphate Approved Phase 3 28014-46-2
42
Mycophenolic acid Approved Phase 3 24280-93-1 446541
43
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
44
Dehydroepiandrosterone Approved, Investigational, Nutraceutical Phase 3 53-43-0 9860744
45
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 3 65-23-6 1054
46 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
47
Cediranib Investigational Phase 3 288383-20-0 9933475
48
Maleic acid Experimental, Investigational Phase 3 110-17-8, 110-16-7 444972
49
Trebananib Investigational Phase 3 894356-79-7
50 Gastrointestinal Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 891)
# Name Status NCT ID Phase Drugs
1 A MULTICENTER STUDY IN PATIENTS WITH STAGE III-IV EPITHELIAL OVARIAN CANCER TREATED WITH CARBOPLATIN/PACLITAXEL WITH BEVACIZUMAB: CLINICAL AND BIOLOGICAL PROGNOSTIC FACTORS Unknown status NCT01706120 Phase 4 Bevacizumab;Paclitaxel;Carboplatin
2 Obligatory Post-Registration Open-Label, Non-Comparative Multicenter Study of Efficacy and Tolerance Rate of Caelyx as Monotherapy in Patients With Epithelial Ovarian Cancer, Resistant to Previous Platinum Therapy. Completed NCT00727961 Phase 4 Pegylated Liposomal Doxorubicin hydrochloride
3 Tumor Gene Expression Before and After Intraoperative Dexamethasone in Women With Ovarian Cancer Completed NCT00817479 Phase 4 Dexamethasone;Placebo
4 Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib in Maintenance After Platine-based Chemotherapy for Patients With Ovarian Cancer Late Relapse : the French GINECO - NiQoLe Study Recruiting NCT03752216 Phase 4 Niraparib
5 An Open Label, Single Arm, Multicentre Study to Assess the Clinical Effectiveness and Safety of Lynparza (Olaparib) Capsules Maintenance Monotherapy in Platinum Sensitive Relapsed Somatic or Germline BRCA Mutated Ovarian Cancer Patients Who Are in Complete or Partial Response Following Platinum Based Chemotherapy (ORZORA). Active, not recruiting NCT02476968 Phase 4 Olaparib
6 Evaluation of PEGylated Doxorubicin Hydrochloride Liposome Injection(Duomeisu®) Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian Cancer: A Randomized, Open, Multicenter Clinical Study Not yet recruiting NCT03794778 Phase 4 pegylated liposomal doxorubicin;paclitaxel;Carboplatin
7 Contrast Enhanced Diffusion-weighted Magnetic Resonance Imaging for Detection of Pathologic Lymph Nodes in Ovarian Cancer - a Feasibility Study. Withdrawn NCT02243059 Phase 4 Gadofosveset trisodium (Ablavar™ )
8 Multicenter Randomized Survival Study of Monoclonal Antibody Radioimmunotherapy: A Multinational Study in Patients With Ovarian Carcinoma Using the HMFG1 Antibody Labeled With 90Yttrium Unknown status NCT00004115 Phase 3
9 An International Phase III Randomised Trial of Dose Fractionated Chemotherapy Compared to Standard Three Weekly Chemotherapy, Following Immediate Primary Surgery or as Part of Delayed Primary Surgery, for Women With Newly Diagnosed Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Unknown status NCT01654146 Phase 3 Carboplatin;Carboplatin;Paclitaxel;Paclitaxel
10 Neoadjuvant Chemotherapy (NACT) Followed by Interval Debulking Surgery vs Upfront Surgery Followed by Chemotherapy (CT) in Advanced Epithelial Ovarian Carcinoma (EOC): A Prospective Randomized Study Unknown status NCT00715286 Phase 3
11 Phase III Randomized Study of Adjuvant Therapy With a Platinum-Containing Regimen (e.g., CBDCA or CAP: CTX/DOX/CDDP) vs No Adjuvant Therapy in Patients With Fully Resected Early Stage Ovarian Cancer Unknown status NCT00002477 Phase 3 carboplatin;cisplatin;cyclophosphamide;doxorubicin hydrochloride
12 Randomized Double-Blind Controlled Phase III Trial of Hyperbaric Oxygen Therapy in Patients Suffering Long-Term Adverse Effects of Radiotherapy for Pelvic Cancer (HOT II) Unknown status NCT01087268 Phase 3
13 A Randomized Phase II/III Trial Comparing Carboplatin-Ifosfamide (IC)-Chemotherapy Vs. IC-Chemotherapy Combined With Extreme Whole Body Hyperthermia In Patients With Recurrence Of Epithelial Ovarian Carcinoma: DOLPHIN-1-STUDY Unknown status NCT00045461 Phase 2, Phase 3 carboplatin;ifosfamide
14 The Phase II Study of Intraoperative Hyperthermic Intraperitoneal Chemotherapy Followed by Intravenous Chemotherapy in Patients With Ovarian Cancer Unknown status NCT01091636 Phase 2, Phase 3
15 Multicenter Phase III Randomized Study With Second Line Chemotherapy Plus or Minus Bevacizumab in Patients With Platinum Sensitive Epithelial Ovarian Cancer Recurrence After a Bevacizumab/Chemotherapy First Line Unknown status NCT01802749 Phase 3 Bevacizumab;Paclitaxel;Carboplatin;pegylated liposomal doxorubicin;Gemcitabine
16 Randomized Phase III Trial of Conventional Paclitaxel and Carboplatin Versus Dose Dense Weekly Paclitaxel and Carboplatin in Patients With Newly Diagnosed Stage II-IV Mullerian Carcinoma Unknown status NCT00226915 Phase 3 Paclitaxel+Carboplatin;Paclitaxel+Carboplatin
17 A Randomised, Placebo-controlled, Trial of Concurrent Cediranib [AZD2171] (With Platinum-based Chemotherapy) and Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer Unknown status NCT00532194 Phase 3 cediranib
18 Phase III Randomized Multicentre Trial of Carboplatin + Liposomal Doxorubicin vs Carboplatin + Paclitaxel in Patients With Ovarian Cancer Unknown status NCT00326456 Phase 3 liposomal doxorubicin;carboplatin;paclitaxel
19 Phase III Multicenter Study in Epithelial Ovarian Carcinoma FIGO Stage IIB-IV Comparing Treatment With Paclitaxel and Carboplatin to Paclitaxel and Carboplatin Sequentially Followed by Topotecan Completed NCT00006454 Phase 3 carboplatin;paclitaxel;topotecan hydrochloride
20 A Randomized, Prospective Phase III Comparison of Paclitaxel-Carboplatin Versus Docetaxel-Carboplatin as First Line Chemotherapy in Stage Ic-IV Epithelial Ovarian Cancer Completed NCT00003998 Phase 3 carboplatin;docetaxel;paclitaxel
21 A PHASE III RANDOMIZED STUDY OF CISPLATIN (NSC #119875) AND TAXOL (PACLITAXEL) (NSC #125973) WITH INTERVAL SECONDARY CYTOREDUCTION VERSUS CISPLATIN AND PACLITAXEL IN PATIENTS WITH SUBOPTIMAL STAGE III & IV EPITHELIAL OVARIAN CARCINOMA Completed NCT00002568 Phase 3 cisplatin;paclitaxel
22 A Multi-National Randomized Phase-III GCIG Intergroup-Study Comparing 1st-line Chemotherapy With Gemcitabine/Paclitaxel/Carboplatin vs Paclitaxel/Carboplatin In Previously Untreated Patients With Epithelial Ovarian Cancer FIGO Stages I-IV Completed NCT00052468 Phase 3 TCG;TC
23 ICON7 - A Randomised, Two-Arm, Multi-Centre Gynaecologic Cancer InterGroup Trial of Adding Bevacizumab to Standard Chemotherapy (Carboplatin and Paclitaxel) in Patients With Epithelial Ovarian Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
24 A Randomized Phase III Study Comparing Gemcitabine Plus Carboplatin Versus Carboplatin Monotherapy in Patients With Advanced Epithelial Ovarian Carcinoma Who Failed First-Line Platinum-Based Therapy Completed NCT00006453 Phase 3 carboplatin;gemcitabine hydrochloride
25 A Randomized Study Of Tamoxifen Versus Thalidomide (NSC# 66847) In Patients With Biochemical-Recurrence-Only Epithelial Ovarian Cancer, Cancer Of The Fallopian Tube, And Primary Peritoneal Carcinoma After First Line Chemotherapy Completed NCT00041080 Phase 3 tamoxifen citrate;thalidomide
26 A Randomised Trial of Interval Debulking Surgery in Epithelial Ovarian Cancer Suboptimally Debulked at Primary Surgery Completed NCT00003695 Phase 3 chemotherapy
27 A Phase III Randomized Trial of Cisplatin (NSC #119875) With Paclitaxel (NSC #125973) Administered by Either 24 Hour Infusion or 96 Hour Infusion in Patients With Selected Stage III and Stage IV Epithelial Ovarian Cancer and Primary Peritoneal Carcinoma Completed NCT00002717 Phase 3 cisplatin;paclitaxel
28 A Phase III Randomized Trial of Intravenous Paclitaxel and Cisplatin Versus Intravenous Paclitaxel, Intraperitoneal Cisplatin and Intraperitoneal Paclitaxel in Patients With Optimal Stage III Epithelial Ovarian Carcinoma or Primary Peritoneal Carcinoma Completed NCT00003322 Phase 3 cisplatin;paclitaxel
29 A Phase 3 Study of Safety and Efficacy of Karenitecin Versus Topotecan Administered for 5 Consecutive Days Every 3 Weeks in Patients With Advanced Epithelial Ovarian Cancer Completed NCT00477282 Phase 3 Karenitecin;Topotecan
30 Multi-Center, Randomized, Double-Blind, Phase III Efficacy Study Comparing Phenoxodiol in Combination With Carboplatin Versus Carboplatin With Placebo in Patients With Platinum-Resistant or Platinum-Refractory Late-Stage Epithelial Ovarian, Fallopian or Primary Peritoneal Cancer Following at Least Second Line Platinum Therapy Completed NCT00382811 Phase 3 phenoxodiol;carboplatin;placebo
31 Amifostine as a Toxicity Protectant in Ovarian Cancer in Chemotherapy Treated Patients: A Pilot Phase III Randomized Controlled Trial Completed NCT00004166 Phase 3 amifostine trihydrate
32 A Randomized Phase III Study Comparing Gemcitabine Plus Carboplatin Versus Carboplatin Monotherapy in Patients With Advanced Epithelial Ovarian Carcinoma Who Failed First-Line Platinum-Based Therapy Completed NCT00102414 Phase 3 Gemcitabine
33 Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian Cancer Completed NCT00850772 Phase 3
34 A Randomized Phase III Trial of Sequential High Dose Chemotherapy or Standard Chemotherapy for Optimally Debulked FIGO Stage III and IV Ovarian Cancer Completed NCT00004921 Phase 3 carboplatin;cyclophosphamide;melphalan;paclitaxel
35 A Randomized, Multicenter, Phase III Study of Erlotinib Versus Observation in Patients With no Evidence of Disease Progression After First Line, Platinum-Based Chemotherapy For High-Risk Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00263822 Phase 3 erlotinib hydrochloride
36 Phase III Randomized Study of TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Liposomal Doxorubicin (Doxil) as Second-Line Therapy in Platinum Refractory or Resistant Ovarian Cancer [ASSIST-3] Completed NCT00102973 Phase 3 TLK286 in Combination with Carboplatin;Doxorubicin HCl Liposome Injection
37 SCOTROC 4: A Prospective, Multicentre, Randomised Trial Of Carboplatin Flat Dosing Vs Intrapatient Dose Escalation In First Line Chemotherapy Of Ovarian, Fallopian Tube And Primary Peritoneal Cancers Completed NCT00098878 Phase 3 carboplatin
38 A Randomized Feasibility Trial to Determine the Impact of Timing of Surgery and Chemotherapy in Newly Diagnosed Patients With Advanced Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Carcinoma Completed NCT00075712 Phase 2, Phase 3 carboplatin;paclitaxel
39 A Multi-National,Randomized, Phase III, GCIG Intergroup Study Comparing Pegylated Liposomal Doxorubicin and Carboplatin Versus Paclitaxel and Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse (> 6 Months) Completed NCT00189553 Phase 3 Pegylated liposomal doxorubicin;Carboplatin;Paclitaxel
40 A Randomized Phase III Double-Blind Study Of Ondansetron And Dexamethasone Versus Ondansetron And Placebo In The Prophylaxis Of Radiation-Induced Emesis Completed NCT00016380 Phase 3 dexamethasone;ondansetron
41 A Randomized Phase III Trial of IV Carboplatin (AUC 6) and Paclitaxel 175 mg/m2 Q 21 Days x 3 Courses Plus Low Dose Paclitaxel 40 mg/m2/wk Versus IV Carboplatin (AUC 6) and Paclitaxel 175 mg/m2 Q 21 Days x 3 Courses Plus Observation in Patients With Early Stage Ovarian Carcinoma Completed NCT00003644 Phase 3 carboplatin;paclitaxel
42 A Phase III Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy Completed NCT00043082 Phase 3 carboplatin;pegylated liposomal doxorubicin hydrochloride
43 Phase III Randomized Trial of 12 Months vs. 3 Months of Paclitaxel in Patients With Advanced Ovarian Cancer Who Attain a Clinically Defined Complete Response (CR) Following Platinum/Paclitaxel-Based Chemotherapy Completed NCT00003120 Phase 3 paclitaxel
44 A Randomized, Parallel Group, Open-label, Active Controlled, Multicenter Phase III Trial of Patupilone (EPO906) Versus Pegylated Liposomal Doxorubicin in Taxane/Platinum Refractory/Resistant Patients With Recurrent Epithelial Ovarian, Primary Fallopian or Primary Peritoneal Cancer Completed NCT00262990 Phase 3 EPO906 (Patupilone);doxorubicin
45 A Two-Part, Randomized Phase III, Double-Blind, Multicenter Trial Assessing The Efficacy And Safety of Pertuzumab In Combination With Standard Chemotherapy Vs. Placebo Plus Standard Chemotherapy In Women With Recurrent Platinum-Resistant Epithelial Ovarian Cancer And Low HER3 mRNA Expression Completed NCT01684878 Phase 3 Gemcitabine (Chemotherapy);Paclitaxel (Chemotherapy);Pertuzumab;Placebo;Topotecan (Chemotherapy)
46 Randomized Trial on Chemosensitivity Testing in Advanced Primary Ovarian Carcinoma (Phase III) Completed NCT00003214 Phase 3 carboplatin;cisplatin;cyclophosphamide;doxorubicin hydrochloride;in vitro sensitivity-directed chemotherapy;paclitaxel
47 A RANDOMISED TRIAL OF PACLITAXEL (TAXOL) IN COMBINATION WITH PLATINUM CHEMOTHERAPY VS. CONVENTIONAL PLATINUM-BASED CHEMOTHERAPY IN THE TREATMENT OF WOMEN WITH RELAPSED OVARIAN CANCER Completed NCT00002894 Phase 3 carboplatin;cisplatin;paclitaxel
48 Global Study to Assess the Addition of Bevacizumab to Carboplatin and Paclitaxel as Front-line Treatment of Epithelial Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Carcinoma Completed NCT01239732 Phase 3 Paclitaxel;Bevacizumab;Carboplatin
49 A Randomized Trial of Paclitaxel/Epirubicin/Carboplatin Combination (TEC) Versus Paclitaxel/Carboplatin (TC) in the Treatment of Women With Advanced Ovarian Cancer Completed NCT00004934 Phase 3 carboplatin;epirubicin hydrochloride;paclitaxel
50 A Randomized Phase III Study Comparing Upfront Debulking Surgery Versus Neo-Adjuvant Chemotherapy in Patients With Stage IIIC or IV Epithelial Ovarian Carcinoma Completed NCT00003636 Phase 3 carboplatin;cisplatin

Search NIH Clinical Center for Ovarian Epithelial Cancer

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Letrozole
Melphalan
Niraparib
Olaparib

Genetic Tests for Ovarian Epithelial Cancer

Genetic tests related to Ovarian Epithelial Cancer:

# Genetic test Affiliating Genes
1 Ovarian Epithelial Cancer 29

Anatomical Context for Ovarian Epithelial Cancer

MalaCards organs/tissues related to Ovarian Epithelial Cancer:

41
Ovary, Breast, T Cells, Testes, Lymph Node, Endothelial, Bone

Publications for Ovarian Epithelial Cancer

Articles related to Ovarian Epithelial Cancer:

(show top 50) (show all 8896)
# Title Authors PMID Year
1
Identification of lncRNA-miRNA-mRNA regulatory network associated with epithelial ovarian cancer cisplatin-resistant. 38
30950060 2019
2
Nuclear orphan receptor NR2F6 confers cisplatin resistance in epithelial ovarian cancer cells by activating the Notch3 signaling pathway. 38
30895619 2019
3
Improved anti-tumor efficacy of paclitaxel in combination with MicroRNA-125b-based tumor-associated macrophage repolarization in epithelial ovarian cancer. 38
31288064 2019
4
Ovarian Cancer in Women of African Ancestry (OCWAA) consortium: a resource of harmonized data from eight epidemiologic studies of African American and white women. 38
31236792 2019
5
Dose-risk relationships between cigarette smoking and ovarian cancer histotypes: a comprehensive meta-analysis. 38
31236793 2019
6
Involved-field radiation therapy for selected cases of recurrent ovarian cancer. 38
31328453 2019
7
Circulating Mitochondrial DNA is Linked to Progression and Prognosis of Epithelial Ovarian Cancer. 38
31271962 2019
8
Maximal-Effort Cytoreductive Surgery for Ovarian Cancer Patients with a High Tumor Burden: Variations in Practice and Impact on Outcome. 38
31243666 2019
9
Prognostic role of pathologic response and cytoreductive status at interval debulking surgery after neoadjuvant chemotherapy for advanced epithelial ovarian cancer. 38
31283034 2019
10
Overexpression of HER2/HER3 and clinical feature of ovarian cancer. 38
31328457 2019
11
Overexpression of long noncoding RNA HOXB-AS3 indicates an unfavorable prognosis and promotes tumorigenesis in epithelial ovarian cancer via Wnt/β-catenin signaling pathway. 38
31337688 2019
12
A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer. 38
31174889 2019
13
Differences in presentation and survival of Asians compared to Caucasians with ovarian cancer: An NRG Oncology/GOG Ancillary study of 7914 patients. 38
31229298 2019
14
Survival disparities among racial/ethnic groups of women with ovarian cancer: An update on data from the Surveillance, Epidemiology and End Results (SEER) registry. 38
31400533 2019
15
Apparent Diffusion Coefficient Histogram Analysis for Assessing Tumor Staging and Detection of Lymph Node Metastasis in Epithelial Ovarian Cancer: Correlation with p53 and Ki-67 Expression. 38
30456593 2019
16
Measurements of adiposity as prognostic biomarkers for survival with anti-angiogenic treatment in epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group ancillary data analysis of GOG 218. 38
31409486 2019
17
Long non-coding RNA GAS5 inhibits DDP-resistance and tumor progression of epithelial ovarian cancer via GAS5-E2F4-PARP1-MAPK axis. 38
31391118 2019
18
A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24. 38
31375879 2019
19
Cytoplasmic and membranous receptor-binding cancer antigens expressed on SiSo cells (RCAS1) immunoreactivity in epithelial ovarian cancer cells represent differing biological function of RCAS1. 38
31388982 2019
20
Combination Treatment with an Antibody-Drug Conjugate (A1mcMMAF) Targeting the Oncofetal Glycoprotein 5T4 and Carboplatin Improves Survival in a Xenograft Model of Ovarian Cancer. 38
31332693 2019
21
1-calcium phosphate-uracil inhibits intraperitoneal metastasis by suppressing FAK in epithelial ovarian cancer. 38
31290719 2019
22
MYH9 overexpression correlates with clinicopathological parameters and poor prognosis of epithelial ovarian cancer. 38
31423165 2019
23
Downregulation of BAG3 attenuates cisplatin resistance by inhibiting autophagy in human epithelial ovarian cancer cells. 38
31423267 2019
24
Evolving Concepts in the Management of Newly Diagnosed Epithelial Ovarian Cancer. 38
31403859 2019
25
Management of Platinum-Resistant, Relapsed Epithelial Ovarian Cancer and New Drug Perspectives. 38
31403868 2019
26
Paeonol induces cytoprotective autophagy via blocking the Akt/mTOR pathway in ovarian cancer cells. 38
31406198 2019
27
Molecular profiling of mucinous epithelial ovarian cancer by weighted gene co-expression network analysis. 38
31108164 2019
28
Overview of imaging findings associated with systemic therapies in advanced epithelial ovarian cancer. 38
31396642 2019
29
Intrinsic Resistance to MEK Inhibition through BET Protein-Mediated Kinome Reprogramming in NF1-Deficient Ovarian Cancer. 38
31043489 2019
30
Targeting IDH1 as a Prosenescent Therapy in High-grade Serous Ovarian Cancer. 38
31110157 2019
31
Diagnosis of epithelial ovarian cancer using a combined protein biomarker panel. 38
31388184 2019
32
Racial and socioeconomic disparities in adherence to preventive health services for ovarian cancer survivors. 38
31172430 2019
33
Vesicular-Bound HLA-G as a Predictive Marker for Disease Progression in Epithelial Ovarian Cancer. 38
31382533 2019
34
Pre-diagnosis body mass index, physical activity and ovarian cancer mortality. 38
31383570 2019
35
Unraveling a difficult diagnosis: the tricks for early recognition of ovarian cancer. 38
31081307 2019
36
TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7). 38
31420412 2019
37
Perceived discrimination, trust in physicians, and prolonged symptom duration before ovarian cancer diagnosis in the African American Cancer Epidemiology Study. 38
31415710 2019
38
Flavonoids showed anticancer effects on the ovarian cancer cells: Involvement of reactive oxygen species, apoptosis, cell cycle and invasion. 38
31128404 2019
39
Outcome of surgery in advanced ovarian cancer varies between geographical regions; opportunities for improvement in The Netherlands. 38
31027945 2019
40
Primary debulking surgery vs. interval debulking surgery for advanced ovarian cancer: review of the literature and meta-analysis. 38
31081304 2019
41
Chemotherapy alone for patients 75 years and older with epithelial ovarian cancer - is interval cytoreductive surgery still needed? 38
31421122 2019
42
Cost-utility analysis of germline BRCA1/2 testing in women with high-grade epithelial ovarian cancer in Spain. 38
30617925 2019
43
Association between the cervicovaginal microbiome, BRCA1 mutation status, and risk of ovarian cancer: a case-control study. 38
31300207 2019
44
Trends in surgical complexity and treatment modalities utilized in the management of ovarian cancer in an era of neoadjuvant chemotherapy. 38
31196575 2019
45
Intraperitoneal α-Emitting Radioimmunotherapy with 211At in Relapsed Ovarian Cancer: Long-Term Follow-up with Individual Absorbed Dose Estimations. 38
30683761 2019
46
Using an evidence-based triage algorithm to reduce 90-day mortality after primary debulking surgery for advanced epithelial ovarian cancer. 38
31402165 2019
47
Oxytocin in the tumor microenvironment is associated with lower inflammation and longer survival in advanced epithelial ovarian cancer patients. 38
31005045 2019
48
Appraising the role of previously reported risk factors in epithelial ovarian cancer risk: A Mendelian randomization analysis. 38
31390370 2019
49
Urinary PGE-M levels and risk of ovarian cancer. 38
31387969 2019
50
Establishment of patient-derived xenograft model in ovarian cancer and its influence factors analysis. 38
31385376 2019

Variations for Ovarian Epithelial Cancer

ClinVar genetic disease variations for Ovarian Epithelial Cancer:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 PIK3CA NM_006218.4(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 3:178952085-178952085 3:179234297-179234297
2 PIK3CA NM_006218.4(PIK3CA): c.1636C> A (p.Gln546Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 3:178936094-178936094 3:179218306-179218306
3 PIK3CA NM_006218.4(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 3:178936091-178936091 3:179218303-179218303

Expression for Ovarian Epithelial Cancer

Search GEO for disease gene expression data for Ovarian Epithelial Cancer.

Pathways for Ovarian Epithelial Cancer

GO Terms for Ovarian Epithelial Cancer

Sources for Ovarian Epithelial Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....